ATE321782T1 - Membrantranslokierendes peptid als wirkstofftransportsystem - Google Patents

Membrantranslokierendes peptid als wirkstofftransportsystem

Info

Publication number
ATE321782T1
ATE321782T1 AT00968159T AT00968159T ATE321782T1 AT E321782 T1 ATE321782 T1 AT E321782T1 AT 00968159 T AT00968159 T AT 00968159T AT 00968159 T AT00968159 T AT 00968159T AT E321782 T1 ATE321782 T1 AT E321782T1
Authority
AT
Austria
Prior art keywords
mtlp
active agent
complex
membrane
active
Prior art date
Application number
AT00968159T
Other languages
English (en)
Inventor
Daniel J O'mahony
Imelda J Lambkin
Original Assignee
Elan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp filed Critical Elan Corp
Application granted granted Critical
Publication of ATE321782T1 publication Critical patent/ATE321782T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00968159T 1999-09-27 2000-09-27 Membrantranslokierendes peptid als wirkstofftransportsystem ATE321782T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15624699P 1999-09-27 1999-09-27

Publications (1)

Publication Number Publication Date
ATE321782T1 true ATE321782T1 (de) 2006-04-15

Family

ID=22558739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968159T ATE321782T1 (de) 1999-09-27 2000-09-27 Membrantranslokierendes peptid als wirkstofftransportsystem

Country Status (7)

Country Link
EP (1) EP1230267B1 (de)
JP (1) JP4799790B2 (de)
AT (1) ATE321782T1 (de)
AU (1) AU7811000A (de)
CA (1) CA2386231C (de)
DE (1) DE60027030D1 (de)
WO (1) WO2001027154A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
AU2002326070A1 (en) * 2001-07-02 2003-01-21 Elan Corporation, Plc Peyers's patch and/or m-celle targeting ligands
AU2002364927A1 (en) * 2001-07-10 2003-06-30 North Carolina State University Nanoparticle delivery vehicle
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
GB0515115D0 (en) * 2005-07-22 2005-08-31 Isogenica Ltd Peptide characterisation
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
KR101971021B1 (ko) * 2014-08-17 2019-04-23 (주)셀리버리 세포 투과성의 향상을 위한 개선된 거대분자 전달 도메인(aMTD) 서열, 이를 코딩하는 폴리뉴클레오타이드, 이를 포함하는 aMTD의 독특한 특징을 확인하는 방법, 이를 포함하는 aMTD 서열을 개발하는 방법
US20160060319A1 (en) 2014-08-27 2016-03-03 Cellivery Therapeutics, Inc. Development of Protein-Based Biotherapeutics That Induced Osteogenesis for Bone Healing Therapy: Cell-Permeable BMP2 and BMP7 Recombinant Proteins (CP-BMP2 & CP-BMP7), Polynucleotides Encoding the Same and Pro-osteogenic Compositions Comprising the Same
US20170029798A1 (en) * 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
EP3334756B1 (de) 2015-08-10 2020-06-17 Cellivery Therapeutics, Inc. Verbessertes rekombinantes protein mit zelldurchlässigem cre (icp-cre) und verwendung davon
EP3334755B1 (de) 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Verbessertes rekombinantes protein des zelldurchlässigen reprogrammierungsfaktors (icp-rf) und verwendung davon
WO2017030323A1 (en) 2015-08-18 2017-02-23 Cellivery Therapeutics, Inc. Cell-permeable (cp)-δsocs3 recombinant protein and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JP3618111B2 (ja) * 1993-11-05 2005-02-09 株式会社 メドレックス 有用物質の送達方法および膜認識シグナル
WO1998047913A2 (en) * 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
AU4281999A (en) * 1998-06-10 1999-12-30 Queen's University Of Belfast, The Peptide

Also Published As

Publication number Publication date
WO2001027154A3 (en) 2002-06-20
WO2001027154A2 (en) 2001-04-19
AU7811000A (en) 2001-04-23
JP4799790B2 (ja) 2011-10-26
DE60027030D1 (de) 2006-05-18
JP2003511464A (ja) 2003-03-25
EP1230267A2 (de) 2002-08-14
CA2386231C (en) 2010-09-14
CA2386231A1 (en) 2001-04-19
EP1230267B1 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
ATE321782T1 (de) Membrantranslokierendes peptid als wirkstofftransportsystem
Eklund et al. Structural comparisons of mammalian, yeast and bacillar alcohol dehydrogenases
HK1107030A1 (en) Oligopeptides for reducing elevated blood urea concentration
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
AR033834A1 (es) Una proteina de fusion para liberar un compuesto a una celula, un metodo para liberar dicho compuesto, un metodo para identificar un peptido penetrador de membranas, y el uso de una proteina de fusion para la manufactura de un agente
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
SE0201863D0 (en) Cell penetrating peptides
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
Takagi et al. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
EP2570429A3 (de) Peptidvakzine mit Seq ID No: 48, 41, 44, 46 oder 78 für tumorassoziierte Antigene exprimierenden Krebs
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
WO2001080896A3 (en) Flavopiridol drug combinations and methods with reduced side effects
Dong et al. Improvement of enzymatic stability and intestinal permeability of deuterohemin-peptide conjugates by specific multi-site N-methylation
CA2435812A1 (en) Process and compositions for peptide, protein and peptidomimetic synthesis
GB2411404A (en) Biologically active peptide conjugates
WO2006052775A3 (en) Peptide anti - tumor agent
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
Vlaskovska et al. Biotransformation of nociceptin/orphanin FQ by enzyme activity from morphine-naive and morphine-treated cell cultures
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
DK0853484T3 (da) Hidtil ukendte MU-opioid-receptorligander: agonister og antagonister
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
Slon-Usakiewicz et al. Design of P1 ‘and P3 ‘Residues of Trivalent Thrombin Inhibitors and Their Crystal Structures
Moll et al. A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges
DE602004011843D1 (de) Die myocardfunktion wiederherstellende peptidsubstanz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties